Humedics Accelerates Academic Marketing for ECM Filler 'Elavie Retuo'

Humedics recently held the 'Elravie Retuo' symposium for medical professionals and related personnel. Photo by Humedics

Humedics introduced 'Elravie Re2O,' presenting a new paradigm for ECM (extracellular matrix) fillers.

On the 28th, Humedics announced that it has been continuously conducting academic marketing activities, including successfully hosting the 'Elravie Re2O' symposium for medical professionals and related personnel. The symposium featured lectures introducing the product and principles of the ECM filler 'Elravie Re2O' and sharing cases of transplantation applications.

During the lectures, Dr. Park Jeyoung of Apgujeong Oracle Dermatology Clinic introduced the principles and transplantation methods of Elravie Re2O. Dr. Choi Hoseong of Piona Clinic presented on the application cases of Elravie Re2O under the eyes, and Dr. Yang Dongjun of CDU Cheongdam Plastic Surgery Clinic shared cases of scar treatment using Elravie Re2O.

Additionally, Dr. Jang Dooyeol of Change Clinic, who participated as the chairperson, expressed expectations, stating, "Elravie Re2O will present a new paradigm as an ECM filler."

Elravie Re2O is a product using acellular human dermal matrix (hADM), which is expected to have skin regeneration effects.

Humedics previously secured domestic distribution rights by signing a business agreement for 'Elravie Re2O' with L&C Bio in November last year.

Elravie Re2O applies L&C Bio's patented human tissue processing technology called 'Alloclean Technology.' This technology enhances safety by removing cells and immune rejection factors within the tissue without damaging the tissue's unique three-dimensional structure. A Humedics representative stated, "We will present a new concept paradigm as an ECM filler and actively promote academic marketing activities."